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Transgenic plants offer a low cost approach for the production of pharmaceutically important and commercially valuable recombinant proteins. Our studies were focused on the plant-based production of human interleukin 2 (hIL-2) and its fusion with proteinase inhibitors, either SPI2 from Galleria mellonella or CMTI from Cucurbita maxima. Finally, five plant expression cassettes were obtained. Three of them contained the single cDNA encoding CMTI I, SPI2 and hIL-2, respectively, while two of them contained the translational fusions, SPI2::hIL-2 and CMTI::hIL-2. In all cases, the transgenes were controlled by the RbcS1 promoter and terminator and the recombinant proteins were targeted to the endoplasmic reticulum. After tobacco transformation five groups of transgenic plants were obtained and analyzed. The level of recombinant proteins was estimated either by Western blot or by ELISA. 






Human interleukin 2 (hIL-2) is a pharmaceutically important cytokine secreted primarily by activated CD4+ T cells and also by CD8+ T cells, some B and dendritic cells. This cytokine plays a central role in regulating immune responses. It activates diverse cells of the immune system, including helper T cells, B cells, macrophages, natural killer cells, and lymphokine-activated killer precursor (Gaffen and Liu, 2004). Recombinant hIL-2 is available as a commercial preparation Proleukin® (aldesleukin; Novartis Pharmaceuticals UK Ltd), mainly used in immunotherapy of metastatic melanoma and kidney cancer  ADDIN EN.CITE (Elias et al., 2008; Gaffen and Liu, 2004; Glaspy, 2002; Petrella et al., 2007). This cytokine has been also tested in HIV infection treatment and therapy of colorectal, gastric, liver and many other cancers  ADDIN EN.CITE (Natarajan et al., 2002; Sereti et al., 2002). Its application as adjuvant for many animals and human vaccines has also been reported  ADDIN EN.CITE (Barouch et al., 2004; Min et al., 2001; Rompato et al., 2006; Wortham et al., 1998; Xie et al., 2007). A major limitation of IL-2 application, beside its toxicity, is a short half-life in vivo and rapid clearance. The production of large quantities of this cytokine in Escherichia coli and baculovirus-infected Trichoplusia ni insects cells is too expensive (Park and Cheong, 2002). Therefore, adaptation of cost-effective plant-based expression system for the production of hIL-2 seems to be justified. Plants have been used as bioreactors for production of many recombinant proteins with therapeutic or biotechnological implications  ADDIN EN.CITE (Golovkin, 2011; Mett et al., 2008; Obembe et al., 2011). The plant-based systems offer an inexpensive, efficient and safe alternative to other commonly used expression systems, which are based on bacterial and yeast cultures, animal cells or transgenic animals  ADDIN EN.CITE (Fischer and Emans, 2000; Horn et al., 2004; Ma et al., 2003; Yusibov et al., 2011). In this study we decided to produce proteins in low alkaloid line of transgenic tobacco. Nicotiana tabacum is considered an attractive plant in such experiments for many reasons, including the fact that tobacco has a high biomass of the leaves and it is a non-food crop, what reduces the risk of contamination of food with undesired transgene or its product  ADDIN EN.CITE (Conley et al., 2011; Ma et al., 2003; Tremblay et al., 2010). Finally, the genetic transformation and expression technology using this crop is well established and relatively facile.




Characterization of transformed tobacco plants
The cDNAs encoding proteinase inhibitors (CMTI and SPI2), hIL-2 and the fusion proteins CMTI/hIL-2 and SPI2/hIL-2 were cloned between the RbcS1 promoter and terminator (Figure 1). All recombinant proteins were targeted to endoplasmic reticulum (ER). Following verification of the functionality of the expression cassettes in a transient expression system (data not shown) the stable genetic transformation of tobacco was performed. Five expression cassettes for the expression of hIL-2, CMTI I, SPI2, CMTI::hIL-2 and SPI2::hIL-2 were introduced into the low alkaloid cultivar of tobacco and five groups of the transformants, IL‑2, CMTI, SPI2, CMTI/IL-2 and SPI2/IL-2, were obtained. Kanamycin-resistant plants were tested for transgene integration by PCR followed by sequencing. This analysis confirmed correct nucleotide sequence of the transgene. No difference in growth and development between transgenic plants and the parental line was observed.

Detection of recombinant proteins
Accumulation of recombinant proteins in the independent primary transformants (T0 generation) was determined by Western blot assay with anti-hIL-2 or anti-cmyc antibody using total protein extracts from their leaves. This analysis confirmed the presence of the protein bands of the expected molecular size for CMTI and SPI2 transformants (Figure 2a). The predicted molecular weights of CMTI I and SPI2 (with 6xHis and cmyc tags) are 6.1 kDa and 6.7 kDa, respectively. In the case of hIL‑2 group of transgenic plants, the Western blot analysis showed one specific band corresponding to the predicted molecular weight of hIL-2 with 6xHis and cmyc tags and without the N-terminal leader peptide (18.14 kDa; Figure 2a), however sometimes a very weak band of about 17 kDa, presumably a degradation product, appeared below the main one. The predicted molecular weights of the CMTI/IL-2 and SPI2/IL-2 fusion proteins are 21.7 kDa and 22.4 kDa, respectively. Western blot analysis of the CMTI/IL-2 and SPI2/IL-2 plants showed a specific band of about 22 kDa in both cases (Figure 2a). Similarly to hIL-2, lower bands of about 17 kDa (weaker than the bands of 22 kDa) were detected sometimes in plants from both groups. The Northern blot analysis clearly indicated presence of only one mRNA band of the expected length in each group of the transgenic plants (data not shown).

Level of recombinant proteins
Twenty independent T0 transformants grown in soil were selected from each of the three groups obtained (IL‑2, CMTI/IL-2 and SPI2/IL-2) for evaluation of the level of recombinant proteins accumulation by ELISA assay. The results for 9 representative plants from each group are shown in Figure 2b. In the IL-2 plants the amounts of recombinant hIL-2 varied from 1.8 to 9.5 µg/g of fresh weight (FW) of leaf tissue and corresponded to 0.014-0.1% of total soluble protein (TSP). The amount of fusion proteins was lower and varied from 0.35 to 3.48 µg/g FW (0.006-0.03%TSP) and from 0.45 to 2.24 µg/g FW (0.0078-0.03% TSP) in CMTI/IL2 and SPI2/IL2 plants, respectively. Preliminary analysis of T1 generation of 2 plants from each kind of transgenic lines indicated that a similar protein production level was retained in the next generation (not shown).


Biological activity of proteinase inhibitors
The measurement of the biological activity of the plant-derived SPI2 and CMTI was performed in vitro by the proteinase (either trypsin or proteinase K) inhibitory activity assay. Protein extracts from the selected individual SPI2, CMTI, SPI2/IL‑2, CMTI/IL‑2 and IL‑2 plants were incubated with one of the proteinases and azocoll (red dye-labeled standard protease substrate). Protein extracts from the hIL‑2 transformant were used as a negative control, while the commercial inhibitor of serine proteases, AEBSF was used as a positive control. The difference in absorbance value between positive and negative samples illustrates an inhibitory effect of recombinant proteinase inhibitors. The higher value denotes proteolysis (more degraded azocoll) that means lower protective activity of the examined proteinase inhibitors. As it is shown in Figure 3a, both inhibitors (CMTI I and SPI2) and both fusion proteins (CMTI/hIL-2 and SPI2/hIL-2) were protecting target standard protein (azocoll) against trypsin enzymatic activity, however, the protection by CMTI I was stronger than the protection by SPI2. In a similar experiment, the activity of SPI2 against proteinase K was demonstrated (Figure 3b). The activity of CMTI I against proteinase K was not tested because of known lack of such activity (Milner et al., 2007). 
In order to determine if the recombinant cytokine produced as a chimeric protein with CMTI I is protected against trypsin the level of hIL-2 was estimated before and after incubation with trypsin by Western blot and ELISA (Figure 4). This assay was performed not only with the samples of the crude plant extract from the respective transgenic plants (as in experiments shown in Figure 3) but also with the partially purified plant-derived recombinant proteins (Figure 4). The applied trypsin ratio to recombinant proteins was 119:1 and 10:1 for plant extract and purified proteins, respectively. Such treatment resulted in decreased amount (to 20%-50% of the amount before treatment, depending on experiment) of plant-derived hIL-2 as well as E. coli-derived hIL-2. In contrast, the fusion protein CMTI/hIL-2 was much less sensitive to the trypsin treatment and its level dropped usually only to 70%-95%. 
Subsequently, the activity of recombinant proteins was evaluated in CTLL-2 cells proliferation assay in order to evaluate the potential activity of hIL-2 remaining after incubation of the crude extracts with trypsin. Prior to the proliferation assay the protein purification on Ni NTA agarose was necessary in order to get rid of trypsin, which might interfere with the cell proliferation.
Biological activity of recombinant hIL-2
The cell-proliferation assay using the IL-2-dependent mammalian cells was used to test the biological activity of the recombinant proteins. In the first approach, the activity of non-purified recombinant hIL-2 in a crude plant extracts was examined. The data obtained clearly indicated that protein extracts from the selected transgenic plants from the IL-2, CMTI/IL-2 and SPI/IL-2 transformants stimulated the proliferation of CTLL-2 cells (Figure S1). The obtained results suggested that plant-derived hIL-2, especially in a fusion with inhibitors might have higher specific activity than the E. coli-derived hIL-2 used as a positive control.
In the second attempt the activities of plant-produced variants of recombinant IL-2 partially purified from the crude extracts incubated with and without trypsin were assayed. A series of two fold dilutions spanning a broad range of protein concentration (IL-2 level was assayed in parallel in ELISA tests) were prepared. As a reference standard and a positive control the commercial E. coli-derived hIL-2 was used in a concentration between 62.5 - 0.24 ng/mL. Moreover, to show wider comparison of hIL-2 produced in various organisms, Pichia pastoris-derived hIL-2 was also tested. As a negative control the cell suspension in medium without cytokine was used. The results of cell proliferation assay indicated that all analyzed proteins were biologically active (Figure 5). The growth curve for cells incubated in medium with E. coli-derived hIL-2 was drawn for concentration in a range of 62.5 – 0.24 ng/mL (the highest value corresponding to 100 % of proliferation). This standard curve could be used to estimate the proliferation index of the plant-derived IL‑2 variants within the range of used two-fold serial dilutions. Detailed comparison of the proliferation indexes with the respective protein concentrations assayed by ELISA indicated that our recombinant proteins displayed specific activity comparable to Pichia pastoris-drived hIL-2, which was higher than activity of hIL-2 produced in E. coli. For example, at the value of proliferation index 60% (corresponding to about 7.8 ng/mL of E-coli-derived IL-2) the concentration of plant-derived hIL-2 was about 0.9 ng/mL, CMTI/hIL-2 - 0.62 ng/mL, SPI2/hIL-2 - 0.31 ng/mL and Pichia-derived IL-2 about 1 ng/mL. One might conclude that from all plant-derived recombinant proteins the hIL-2/SPI2 fusion demonstrated the highest activity, however the difference was not statistically significant if all serial dilutions were considered.

Discussion
The main goal of our study was efficient production of biologically active recombinant hIL-2 in transgenic tobacco plants. For this purpose we used expression cassettes containing the promoter of the Rubisco small subunit from Asteraceous chrysanthemum, which potentially can provide 8-fold higher expression than the 35S promoter from cauliflower mosaic virus (35S CaMV)  ADDIN EN.CITE (Outchkourov et al., 2003a). Additionally, the endoplasmic reticulum (ER) retention signal, KDEL, was added at the C-terminus of all recombinant proteins. Comparing to the strategy of targeting proteins into cytoplasm this strategy may enhance up to 5-fold accumulation of recombinant proteins in plants, mainly because the ER contains lower concentration and/or different proteases responsible for post-transcriptional degradation  ADDIN EN.CITE (Outchkourov et al., 2003b). The applied approach allowed us to achieve the yield of 0.35-9.5 µg/g of fresh tissue which makes up to 0.1% of TSP in T0 generation of the transformants grown in soil.
Only two attempts of recombinant hIL-2 production in plants have been reported so far. The first one concerned production in cell suspension of N. tabacum (Magnuson et al., 1998). The transgene expression was driven by 35S promoter from CaMV and the production achieved the level of 0.9 µg/mL of medium. Interestingly, most of the protein (0.8 µg of hIL-2/mL) was retained inside the transgenic tobacco cells. The second report concerned production of hIL-2 in tubers of transgenic potato plants (Park and Cheong, 2002). The cDNA of hIL-2 was cloned under the control of the tuber specific patatin promoter. The maximum yield of 115 ng/g was achieved in two-week old micro tubers.
In this study tobacco plants were used to produce recombinant hIL-2 in leaf tissues. Because of different system than the one used in work discussed above (tobacco suspension cells and potato tubers) we cannot make reliable comparison of the efficiency. Previously, using exactly the same plant expression system we reported about two-fold higher accumulation of recombinant murine granulocyte-macrophage colony stimulating factor, mGM-CSF  ADDIN EN.CITE (Gora-Sochacka et al., 2010) than the accumulation of hIL-2 reported in this study. However, we have to take into account that GM-CSF was N-glycosylated in plants, what probably increased its stability. To improve the stability of recombinant hIL-2 we designed constructs with translational fusions of hIL-2 with proteinase inhibitors. Production of fusion proteins in tobacco leaves reached up to 3.48 µg/g of FW (for CMTI/hIL-2) and up to 2.24 µg/g FW (for SPI2/hIL-2). The yield was about 5-fold lower than in the case of hIL‑2 produced without fusion (Figure 2b). The explanation of this finding is not so obvious, however several possibilities can be considered. First of all we analyzed only 20 plants for each group of transformants. More extensive analysis might reveal plants with higher expression levels of CMTI/IL-2 or SPI/IL-2. The expression level of the transgene is highly dependent on its place of integration into plant genome and on a number of copies introduced. More copies means usually higher expression level but it also raises a risk of gene-silencing. We started segregation tests to attain stable transgenic lines. The reason of lower recombinant production might be also dependent on a nature of protein and construction of an expression cassette especially in the case of fusion proteins that are in fact artificial and might show unstable. Indeed in some plant extracts in Western blot besides the main band of expected size, another one weaker and smaller of about 17 kDa was visible (Figure 2a). That may suggest degradation of fusion protein into its component. However, it should be stressed that the strong dissociation was never observed. Besides, the recombinant hIL-2 itself is not highly stable and in some plant extracts additional band (presumably the degradation product) was also detected when hIL-2 was produced without proteinase inhibitors.
In fact, more important factor than the expression level is the biological activity of the recombinant proteins produced in heterologous systems. The protease inhibitor activity of recombinant SPI2 and CMTI I (produced with or without fusions to other proteins) and their usefulness for protection of their fusion partners from proteolytic degradation has been previously investigated (Milner et al., 2007). The four fusion proteins were obtained: SPI::CP, SPI::GUS, CMTI::CP and CMTI::GUS (CP denotes the coat protein of Potato virus Y; GUS denotes β-glucoronidase from E. coli). All recombinant proteins were produced in bacterial expression system, purified and subjected to enzymatic and molecular analysis. Recombinant SPI2 retained its inhibitory activity but CMTI was active only when it was fused to CP. Moreover, fusion with SPI2 did not influence the self-assembly of CP and only slightly decreased the enzymatic activity of GUS. Whereas in the CMTI fusions the specific functions of both target proteins were strongly hampered. Since it is known from literature that both target proteins, CP and GUS, should easily tolerate linked polypeptides at their N-terminus, the authors concluded that differences observed may result from the impact exerted on the target protein by the inhibitory domain. It is known that the structure and folding process of SPI2 are very stable therefore, the additional domain fused to its C-terminus should be well tolerated and folding of both fusion domains should be proper. Contrary to SPI2 the stability and folding process of CMTI may easily be affected even by one amino acid mutation. Therefore, contrary to SPI2, CMTI homologues are not detected in multidomain proteins that may reflect the evolutionary tolerance of functional fusion of SPI2 like domains with other polypeptides. The results of our work are slightly different than the work described by Milner et al. (2007). On the other hand, we used different cloning strategy. In our constructs the sequences encoding CMTI and SPI2 are separated from hIL-2 cDNA by the sequences coding His-tag, c-myc-tag and GSG linker that gives in total a distance of 21 amino acids in recombinant fusion proteins. The biological activities of both proteainase inhibitors as well as hIL-2 were maintained. We demonstrated the protective effect of both plant-derived proteinase inhibitors against trypsin using azocoll as an external substrate (Fig. 3a). As expected, CMTI, which is known as strong trypsin inhibitor, showed quite high activity. Actually, the wild type SPI2 inhibits trypsin very weak. For this reason we used the SPI2 mutant carrying tyrosine in the position 5 instead of threonine known to have a changed substrate specificity (B. Kłudkiewicz, IBB PAS – personal communication) and we demonstrated its low activity against trypsin. We also confirmed its activity against another serine protease, proteinase K (Figure 3b). The results concerning trypsin assay shown in Figure 4 suggest slightly higher activity of SPI2/hIL-2 than SPI2 that needs some explanation. The experiment was performed using crude protein extract of transgenic plants and the total soluble protein (TSP) levels were similar in all analyzed samples. The concentration of recombinant hIL-2 and SPI2/hIL-2 as well as their ratio to TSP were also similar in relation to hIL2. On the other hand, we could not estimate the exact level of proteinase inhibitor because of unavailability of ELISA assay. Therefore, a possible reason of such observed discrepancy could be the higher concentration of SPI2/hIL-2 than SPI2 used in the assay.
Our preliminary observation that much lower degradation of hIL-2 was observed for the fusion protein CMTI/hIL-2 than for hIL-2 without fusion after incubation of crude protein extracts with trypsin (not shown) led us to the conclusion that beside protective activity of CMTI on azocoll used as an external protein the CMTI can also protects its partner in a fusion, hIL-2. However, considering the complex composition of plant extract, which might influence trypsin activity, the additional experiment was performed using purified proteins. The results of this experiment confirmed that CMTI to some extent protects its fusion component against protease activity (Figure 4).
The plant-derived variants of human IL-2 were biologically active as demonstrated by the proliferation assay of CTLL-2 cell line, which growth is IL-2 dependent. The crude protein extracts from transgenic plants had biological activity of IL-2, namely was able to stimulate the growth of IL-2 dependent cells, even at dilution of 6 x 10-3 in the case of transgenic plant with rather low expression of the recombinant protein (Figure S1). The results obtained during this experiment suggested also higher activity of plant-derived hIL-2, especially in a form of fusion protein, than the bacterial-derived hIL-2. Therefore, the similar experiments were performed with partially purified variants of plant-derived hIL-2 and Pichia pastoris-derived hIL-2. The data confirmed high activity of plant-derived recombinant proteins (Figure 5). Moreover, the hIL-2 in fusion with proteinase inhibitors, especially SPI2, showed slightly higher activity. This could be explain by the possibility of the protective activity of this inhibitor against some proteases arising in a cell culture during cultivation (Figure 5). In addition, the purified samples of hIL-2 and CMTI/hIL-2 after trypsin digestion were used. The chosen condition of digestion resulted in 50% decrease of the hIL-2 concentration. In such samples the hIL-2 activity should be retained, however the difference between samples after and before digestion could be detected. The amount of hIL-2 and CMTI/hIL-2 in the samples after trypsin treatment was calculated considering IL-2 degradation by trypsin (as visualized by Western blot and evaluated by ELISA test). Because the concentration of hIL-2 after trypsin digestion is much lower the adequately reduced activity is expected. However, paradoxically at lower dilutions (e.g. dilutions 1 and 2 of IL-2 td; Figure 5b) it even seems as if hIL‑2 has higher activity after the trypsin treatment. This is probably an effect of reaching the saturation level by IL-2 as a growth factor because at higher dilution (e.g. dilutions 3 to 6 of IL-2 td, Figure 5b) the strong decrease of proliferation index was observed. The results shown in Figure 5a, b indicate that the residual forms of hIL-2, which were detected by Western blots and ELISA after trypsin digestion of the crude extracts containing hIL-2, CMTI/hIL-2 retained the biological activity of the cytokine and that the trypsin treatment did not affect the specific activity of the recombinant variants of IL-2 (Figure 5a, b).
In summary, we have demonstrated the possibility and justified the reasons for using low molecular weight proteinase inhibitors such as CMTI and SPI2 as fusion partners with pharmaceutically important protein-hIL-2 to achieve recombinant protein expression in plants. Despite observed slight instability, the chimeric proteins as well as recombinant hIL-2 displayed quite high specific activity. The promising results of this study are encouraging for further similar experiments using different type of the fusion partners.

Experimental procedures
Construction of plasmids for plant transformation
The cDNA of hIL-2 (GenBank Acc No S77834) was amplified with Pfu polymerase (Fermentas, Vilnius, Lithuania), using the recombinant plasmid pVRC-hIL/Ig carring cDNA of hIL-2, kindly provided by Dan Barouch  ADDIN EN.CITE (Barouch et al., 2000) as a template and NcohIL2 (5’-TCCCATGGCACCTACTTCAAG-3’) and BglhIL2 (5’-TTAGATCTGTTAGTGTTGAGA-3’) as primers in the following PCR reaction (4 min 94oC; 30 cycles [45s 94oC, 45s 57oC, 1 min 73oC]; 3min 73oC). The PCR product containing cDNA encoding hIL-2 without N-terminal signal sequence was cloned into the NcoI/BglII sites of the ImpactVector 1.3 tag(Plant Research International, Wageningen; Netherlands [http://www.pri.wur.nl/UK/products /ImpactVector/]). Subsequently, the expression cassette (encoding hIL-2 with the C-terminal ER retention signal) was excised using PacI and AscI and subcloned into the corresponding sites of the binary vector pBINPLUS (Plant Research International, Wageningen, Netherlands) carrying nptII gene providing kanamycin resistance of the transgenic plants. 
The plasmids containing SPI::hIL-2 and CMTI::hIL-2 expression cassettes were constructed in several steps. In the first step, the mutant allele of SPI2 (GenBank Acc No AAK48526) containing two point mutation (substitution of AC into TA resulting in Thr-5 change into Tyr-5), and the CMTI I cDNA encoding the wild type protein (Swiss-Prot Acc No P01074) was amplified from the recombinant plasmids kindly provided by Krystyna Grzelak and Barbara Kłudkiewicz (IBB PAS), using Pfu polymerase (Fermentas, Vilnius, Lithuania) and the respective pairs of primers: NcoSPI (5’-TTCCCATGGTTTGCACCTACGAGTGG-3’) and BglIISPI (5’-TTGAGATCTGCACATTCACCTTCATGATC-3’) for amplification of SPI2, and NcoCMTI (5’-TATCCATGGCGCGTGTTTGCCCGCGTATCCTGATG-3’) and BglIICMTI (5’-ATTAGATCTGCACCGCAGTAACCGTGTTCC-3’) for amplification of CMTI-I. Amplification in both cases was performed in the following conditions (4 min 92oC; 3 cycles [30s 92oC, 30s 54oC 30s 72oC]; 30 cycles [30s 92oC, 30s 61oC 30s 72oC]; 4min 72oC). Following digestion with NcoI and BglII, the PCR products were cloned each into the corresponding sites of the ImpactVector1.3tag vector. Resulting recombinant plasmids ImpactVec1.3tag/SPI2 and ImpactVec1.3tag/CMTI contain inserts encoding SPI2 and CMTI I, each with the C-terminal ER retention signals. They were subsequently used as templates for the next PCR reactions with appropriate primers pairs, namely NcoSPI plus HisGSG (5’-ACCGGATCCGTGATGGTGATGGTGATGAAGATC-3’) and NcoCMTI plus HisGSG for ImpactVec1.3tag/SPI2 and ImpactVec1.3tag/CMTI, respectively. This allowed amplification of SPI2 and CMTI I cDNAs along with the 3’-end sequences encoding cmyc-tag, His-tag and a GSG (Glycine-Serine-Glycine) linker. In parallel, the hIL-2 cDNA with sequences encoding GSG linker at 5’ end of cytokine was amplified using the GSGIL2 (5’-CACGGATCCGGTGCACCTACTTCAAGT-3’) and SacIL2 primers. All three PCR products were purified and combined in two “fusion PCR reactions” for obtaining the final SPI::hIL-2 and CMTI::hIL-2 cassettes schematically shown in Fig.1. The oligonucleotides pairs NcoSPI plus SacIL2 and NcoCMTI plus SacIL2 were used as primers, while the described above PCR products SPI plus hIL-2 and CMTI plus hIL2 were used as templates for SPI::hIL-2 and CMTI::hIL-2 cassettes, respectively. The PCR cycle was as following: (4 min 94oC; 3 cycles [30s 92oC, 30s 45oC, 45s 72oC]; 30 cycles [30s 94oC, 30s 62oC, 45s 7oC]; 3min 72oC). The digested PCR products were cloned into NcoI/SacI sites of ImpactVector 1.3. Finally, the SPI::hIL-2 and CMTI::hIL-2 expression cassettes were re-cloned into the PacI/AscI sites of the pBINPLUS binary vector. The pBINhIL-2KDEL, pBIN/SPI2/hIL-2 KDEL and pBIN/CMTI/hIL-2KDEL binary vectors were used to transform LBA4404 strain of Agrobacterium tumefaciens. The sequences containing sites for restriction enzymes, which were additionally included to facilitate cloning, are underlined in the primers.

Transient and stable plant transformation
Agroinfiltration of Nicotiana tabacum leaves was done exactly as described previously  ADDIN EN.CITE (Gora-Sochacka et al., 2010). After confirmation of the functionality of the expression cassettes in transient expression system, Agrobacterium carrying one of the recombinant plasmids pBIN/SPI2/hIL-2KDEL, pBIN/CMTI/hIL-2KDEL or pBINhIL-2KDEL were used to transformed seedlings of N. tabacum LA Burley 21 (Legg et al., 1970). The transformation procedure was performed according to the method described by Rossi (Rossi et al., 1993). Plants were grown on MS medium (Murashige and Skoog, 1962) supplemented with MS vitamins and kanamycin (150µg/mL). The initial screening of regenerated “plantlets” included sequencing of the PCR products amplified using the plant genomic DNAs as a template with appropriate primers corresponding to the RbcS1 promoter (5’-GGTGTGTATCAATAGGAACTAATTCAC-3’) and terminator (5’-ACCGACTCGTTACAAGAAGG-3’). The confirmed transformants were micropropagated and maintained both in vitro (for analysis) and in vivo (for both, analysis and seed production). Plants cultivated in vitro were kept in a sterile containers in a culture room in the following conditions: 24oC, day/night cycle 16h/8h. Plants grown in vivo were maintained in soil in the controlled greenhouse conditions. The seeds of the chosen transformants containing transgene inserted into a single locus (verified by the segregation of kanamycin resistance) were sown to obtain plants of T1 generation.

Protein extraction
Leaves frozen in liquid nitrogen were ground in extraction buffer (in a ratio of 100 mg of leaf tissue/100 µl of extraction buffer) with composition depending on application. For ELISA assay and Western blot extraction buffer contained 50 mM Tris-HCl, 1 mM EDTA 0.05% β-mercaptoethanol, pH 8. For hIL-2 bioassay 1xPBS buffer containing 150 mM NaCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl and 0.1% Tween20 was used. For the protease inhibitor activity assay the buffer was composed of 50 mM Tris-HCl, 2% PVP, pH 7.5. The homogenate was centrifuged at 10 000 rpm for 15 min at 4oC. The soluble protein concentration in the extracts was determined by Bradford assay (BioRad, Chicago, IL, USA). For the hIL-2 bioassay the supernatants were additionally filter-sterilized using 0.2 µm membranes (Millipore, Germany).

Western blot and ELISA
The total soluble protein extracts (approximately 25 µg/well) were separated on 15% Tris-glycine SDS-PAGE gels or Nu-Page 4-12% gel (Invitrogen, Basel, Switzerland) and subsequently transferred to a nitrocellulose membrane (Hybond-C Extra, Amersham Biosciences, Uppsala, Sweden). In the case of proteinase inhibitors the 16% Tricine-Tris-SDS-PAGE gel according to the described protocol was used (Schägger, 2006). For detection of the recombinant proteins appropriate antibodies such as a polyclonal rabbit against human IL-2 (LabEmpire/BioShop Canada Inc, Burlington, Canada) or monoclonal mouse against human oncogene c-myc (EQKLISEEDL) (Sigma, Deisenhofen, Germany) and Western Breeze chromogenic Western blot immunodetection kit (Invitrogen, Basel, Switzerland) were used. The PageRulerTM Prestained Protein Ladder (10-200 kDa, Fermentas, Vilnius, Lithuania) was used as a molecular weight marker.
A serial two-fold dilutions of plant protein extracts between 1x10-3 to 6.4 x10-4 were tested by a sandwich ELISA, exactly as described by manufacturer’s protocol (Elisa MAXTM Set Deluxe, Biolegend, San Diego, CA, USA). 

Purification of recombinant IL-2 and its fusion with proteinase inhibitors
Recombinant hIL-2 and its fusion with proteinase inhibitors were 6xHis tagged that allow their simple purification using Ni-NTA Agarose (Invitrogen). The leaf samples (10 g) owere homogenized with 4 volumes of extraction buffer (1xPBS, 2mM imidazol, 3% glycerol, 0.2% Tween, pH 7.5). The homogenate was filtered through two layers of miracloth and centrifuged two times at 15000 rpm for 15 min. to remove insoluble materials. The supernatant was filtered through 0.45 µm filter (Roche) and then incubated 20h with 400 µl Ni-NTA Agarose. Next day agarose was rinsed with washing buffer (1xPBS, 2mM imidazol, pH 6.8) to remove nonspecifically bound tobacco proteins. The recombinant proteins were eluted with elution buffer (1x PBS, 500 mM imidazol, pH 6.8).The eluted fractions were dialyzed against 1xPBS, pH 7.5 to remove imidazol. All procedures were performed at 4oC. The purified proteins (hIL-2, CMTI/hIL-2 and SPI/hIL-2) were used in biological activity assays such as trypsin digestion and CTLL-2 cells proliferation assay.

Biological activity assay
Biological activity of recombinant plant-produced hIL-2, hIL::SPI2 and hIL-2::CMTI were assessed using the IL-2 dependent cell line CTLL-2 (American Type Culture Collection, Manassas, VA, USA). During the experiment the suspension culture of CTLL-2 was maintained at 37oC with 5% CO2 on 96-well plates in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, 0.5 mM sodium pyruvate, and T-STIMTM with ConA (IL-2 culture supplement, rat; BD Biosciences, USA). Samples of serial two-fold dilutions of the recombinant proteins purified or protein extracts from either the transgenic or nontransgenic plants were mixed with CTLL-2 cells (2x104 cells/well) in a final volume of 200 µl. As a reference, the cells were supplemented with serial two-fold dilutions of recombinant hIL-2 (LabEmpire/BioShop Canada Inc, Burlington, Canada) in a wide range of 62.5 to 0.24 ng/mL or RPMI medium alone. Each sample was assayed in triplicate. The viability of the cells was quantified using Cell-Titer 96® Aqueous One Solution method (Promega, Madison, WI, USA) or the MTT Cell Proliferation Assay (American Type Culture Collection, Manassas, VA, USA). Proliferation index was calculated as following: (cells, effector agent mix – cells, medium mix / cells, 62 ng/mL E.coli-derived IL-2 mix – cells, medium mix) x 100.

Determination of the proteinase inhibitor activity
The enzymatic activity of the plant-produced recombinant proteinase inhibitors was measured using azocoll as a substrate and trypsin or proteinase K as target enzymes of proteinase inhibitors. Azocoll was prepared by washing for 2 h in 50 mM Tris-HCl, pH 7.5. After centrifugation at 4000 rpm for 10 min at RT the pellet was re-suspended in a fresh buffer to the final concentration of 15 mg/ml. About 100 μg of the total soluble protein (TSP) extracts prepared from the transgenic or control plants were transferred into the well of a 96-well microplate. As positive control serine protease inhibitor AEBSF (2-[Aminomethyl]-benzenesulfonylfluoride, HCL, LabEmpire/BioShop Canada Inc, Burlington, Canada) was used. Trypsin (25 μg/mL) or proteinase K (25 μg/mL) and azocoll (15 mg/mL) mixture were prepared in 50 mM Tris-HCl pH 7.5 and added to protein extract at 1:1 (v/v) ratio. The plate was incubated at 37oC for 2h and centrifuged at 1600 rpm for 2 min at 4oC. The clear supernatants were transferred to a fresh microplate and read at 490nm.
The protection assay of hIL-2 in a fusion with CMTI against trypsin digestion was performed in 25oC. The protein extract prepared in a buffer containing 1xPBS, 1mM EDTA, 0.05% β-mercaptoethanol supplemented with trypsin in a ratio 1:42 (trypsin:TSP, w/w) was incubated for 30 minutes. Alternatively the purified proteins were digested with trypsin in the same condition with exception of trypsin ratio to purified protein 10:1(w/w).
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Figure 1 Expression cassettes used in this study for expression of hIL2, CMTI, SPI2 (a) or the fusion proteins (b). P RbcS1 and T RbcS1, promoter and terminator of Rubisco small subunit from Asteraceous chrysanthemum, respectively; PS, signal peptide from Anemone equistation; HIS and C-myc, detection tags; GSG, a tripeptide (Gly-Ser-Gly) added as a linker between protease inhibitor and hIL-2; inh, CMTI or SPI2 depending on the construct; X, hIL-2, CMTI or SPI2 depending on the construct; K (KDEL), ER-retention signal at C-terminus of the protein; AscI, PacI, NcoI and BglII, restriction enzyme sites.
Figure 2 Detection and evaluation of the production level of the recombinant proteins in the representative tobacco primary transformants (T0) grown in soil. (a) Western blot analysis of the expression of SPI2, CMTI, hIL-2, CMTI/hIL-2 and SPI2/hIL-2, respectively, in the individual transformants indicated by numbers. Twenty five microgram of TSP (total soluble protein) from leaves were separated on SDS-PAGE gel and analyzed by western blotting using anti-hIL-2 or anti-cmyc antibody (for CMTI and SPI2). C+, E. coli-derived purified recombinant hIL-2 (without His and cmyc-tag); C-, untransformed plant; M, molecular marker (size indicated). (b) Quantification of recombinant hIL-2 by ELISA assay in the representative plants. 
Figure 3 Bioactivity assay of the plant-produced recombinant inhibitors of proteases. Protein crude extracts from the lyophilized leaves of transgenic plants IL-2, CMTI, SPI2, CMTI/IL and SPI2/IL were incubated with trypsin (a) or proteinase K (b). using azocoll as a substrate. AEBSF, a commercial serine protease inhibitor.
Figure 4 Protection of the recombinant proteins against trypsin digestion. The plant-derived partially purified hIL-2 and CMTI/hIL-2 and E. coli-derived hIL-2 were incubated with trypsin for 30 minutes at 25oC. Western blot was performed with the samples before digestion (0’) and after trypsin digestion (30’) using anti-IL-2 antibodies. The position of the molecular weight marker (M) is indicated.

Figure 5 Biological activity of the recombinant variants of hIL-2. CTLL-2 cells were incubated with serial two-fold dilutions of the respective proteins. E. coli-derived hIL-2 (IL-2 E.coli) was used as a standard and its serial two-fold dilutions (1 to 9) correspond to the concentration of 62.5, 31.25, 15.6, 7.8, 3.9, 1.95, 0.95, 0.48, 0.24 ng/mL, respectively. The serial dilutions (1 to 9) of P. pastoris IL-2 correspond to 4.6, 2.3, 1.15, 0.57, 0.28, 0.14, 0.07, 0.035, 0.017 ng/mL, respectively. All plant-derived recombinant variants of hIL-2 were quantified by ELISA. The dilution (1 to 8) of the plant-derived hIL‑2 correspond to 7.18, 3.59, 1.8, 0.9, 0.45, 022, 011, 0.055 ng/mL, respectively. The dilutions (1 to 7) of CMTI/IL-2 correspond to 5, 2.5, 1.25, 0.625, 0.312, 0.156, 0.078 ng/mL, respectively. The dilutions (1 to 7) of SPI2/IL-2 correspond to 2.5, 1.25, 0.625, 0.312, 0.156, 0.078, 0.039 ng/mL, respectively. hIL-2 td and CMTI/IL-2 td denote the plant-derived hIL-2 and CMTI/IL-2 purified from the respective trypsin-digested extracts. Their serial dilutions correspond to 3.59, 1.79, 0.89, 0.44, 0.22 ng/mL in the case of hIL-2 td and to 4.3, 2.18, 1.09, 0.5, 0.25, 0.125 ng/mL in the case of CMTI/IL-2 td. Proliferation index is presented as a mean of two independent experiments each performed in triplicate (n=6) with standard deviation (SD) not exceeding 15 %. The lower and upper horizontal scales represent log of protein concentration and the serial dilutions, respectively. Medium+cells denotes a negative control without cytokine (medium mix).
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